PULSION Medical Systems SE

  • WKN: 548790
  • ISIN: DE0005487904
  • Land: Deutschland

Nachricht vom 02.05.2012 | 17:55

Pulsion Medical Systems SE: Publication according to § 26 paragraph. 1 WpHG with the objective of Europe-wide distribution


Pulsion Medical Systems SE 

02.05.2012 17:55

Dissemination of a Voting Rights Announcement, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------


On May 02, 2012, FORUM European Smallcaps GmbH, München, Deutschland has
informed us according to Article 21, Section 1 of the WpHG that via shares
its Voting Rights on Pulsion Medical Systems SE, München, Deutschland, have
exceeded the 3%, 5%, 10%, 15%, 20%, 25%, 30% and 50% threshold of the
Voting Rights on April 30, 2012 and on that day amounted to 52.06% (this
corresponds to 4633543 Voting Rights).
According to Article 22, Section 2, WpHG, 29.38% of the Voting Rights (this
corresponds to 2615004 Voting Rights) is to be attributed to the company.
Voting rights of the stockholders Forum Private Equity GmbH and Prof. Klaus
Kühn, whose voting interest in Pulsion Medical Systems SE amounts to 3% or
more are attributed to FORUM European Smallcaps GmbH.

 



02.05.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      Pulsion Medical Systems SE
              Joseph-Wild-Strasse 20
              81829 München
              Germany
Internet:     www.pulsion.com
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------

Anleihe im Fokus

7,75% p.a. - Rendite aus Familienhand

– Zeichnungsstart: 23. Mai – Börse Frankfurt
– Zeichnung ab 1.000 Euro
– Laufzeit 5 Jahre
– WKN: A1TNA7
– 100% Rückzahlungskurs

GBC-Fokusbox

Syzygy AG: Aktie kaufen

Die nach den ersten drei Monaten des laufenden Jahres von Syzygy präsentierten Zahlen liegen im Rahmen unserer Erwartungen. Angesichts unserer unveränderten Prognosen behalten wir das bisherige Kursziel von 5 € bei und erneuern das Rating KAUFEN.

Event im Fokus

38. m:access Analystenkonferenz München

Datum: 06.06.2013
Zeit: 9:30 Uhr - 17.00 Uhr
Ort: Börse München



Aktuelle Research-Studie

Viscom AG

Original-Research: Viscom AG (von Vara Research GmbH): Halten

22. Mai 2013